[go: up one dir, main page]

NO20041386L - Combinations for the treatment of immuno-inflammatory disorders - Google Patents

Combinations for the treatment of immuno-inflammatory disorders

Info

Publication number
NO20041386L
NO20041386L NO20041386A NO20041386A NO20041386L NO 20041386 L NO20041386 L NO 20041386L NO 20041386 A NO20041386 A NO 20041386A NO 20041386 A NO20041386 A NO 20041386A NO 20041386 L NO20041386 L NO 20041386L
Authority
NO
Norway
Prior art keywords
immuno
combinations
treatment
inflammatory disorders
disorders
Prior art date
Application number
NO20041386A
Other languages
Norwegian (no)
Inventor
Curtis Keith
Nicole Hurst
Palaniyandi Manivasakam
Edward Roydon Jost-Price
Grant Zimmerman
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23277540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20041386(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of NO20041386L publication Critical patent/NO20041386L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20041386A 2001-10-05 2004-04-02 Combinations for the treatment of immuno-inflammatory disorders NO20041386L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32767401P 2001-10-05 2001-10-05
PCT/US2002/031866 WO2003030823A2 (en) 2001-10-05 2002-10-04 Combinations for the treatment of immunoinflammatory disorders

Publications (1)

Publication Number Publication Date
NO20041386L true NO20041386L (en) 2004-05-11

Family

ID=23277540

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041386A NO20041386L (en) 2001-10-05 2004-04-02 Combinations for the treatment of immuno-inflammatory disorders

Country Status (26)

Country Link
US (3) US7253155B2 (en)
EP (2) EP2279742A3 (en)
JP (1) JP2005508346A (en)
KR (2) KR100917082B1 (en)
CN (1) CN100400044C (en)
AR (1) AR036741A1 (en)
AT (1) ATE502642T1 (en)
AU (1) AU2002334870B2 (en)
BR (1) BR0213100A (en)
CA (1) CA2461946C (en)
DE (1) DE60239558D1 (en)
DK (1) DK1448205T3 (en)
ES (1) ES2363334T3 (en)
HR (1) HRP20040388A2 (en)
IL (1) IL161267A0 (en)
IS (1) IS7202A (en)
MX (1) MXPA04003266A (en)
NO (1) NO20041386L (en)
NZ (1) NZ532310A (en)
PL (1) PL370764A1 (en)
PT (1) PT1448205E (en)
RU (1) RU2322984C2 (en)
SI (1) SI1448205T1 (en)
TW (1) TWI247605B (en)
WO (1) WO2003030823A2 (en)
ZA (1) ZA200402955B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411938B1 (en) * 2001-07-02 2005-07-06 Tas, Sinan Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis
EP2279742A3 (en) * 2001-10-05 2011-04-20 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
ATE467123T1 (en) 2003-03-26 2010-05-15 Synergy Biosystems Ltd METHOD FOR IDENTIFYING BIOLOGICALLY ACTIVE AGENTS AND SYNERGISTIC COMBINATIONS
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP2468266A3 (en) * 2004-04-22 2012-10-24 AcuCort AB Pharmaceutical compositions for acute glucocorticoid therapy
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US7799331B2 (en) * 2005-08-04 2010-09-21 Taro Pharmaceutical North America, Inc. Oral suspension of prednisolone acetate
WO2007139753A2 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
WO2007150063A2 (en) * 2006-06-23 2007-12-27 Cargill Incorporated Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements
JP5519500B2 (en) 2007-07-23 2014-06-11 ザ チャイニーズ ユニバーシティー オブ ホンコン Determination of nucleic acid sequence imbalance
US12180549B2 (en) 2007-07-23 2024-12-31 The Chinese University Of Hong Kong Diagnosing fetal chromosomal aneuploidy using genomic sequencing
CA2737131A1 (en) * 2007-09-19 2009-03-26 Zalicus Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
JP2011506607A (en) * 2007-12-17 2011-03-03 ザリカス インコーポレイティッド Therapies for the treatment of immunoinflammatory disorders
BRPI0909541A2 (en) * 2008-05-27 2016-10-11 Pluristem Ltd '' method for treating inflammatory bowel disease ''
EP2566456A4 (en) * 2010-05-06 2013-09-25 Nuvo Res Inc TRIAMCINOLONE ACETONIDE FORMULATIONS FOR THE TREATMENT OF DERMATITIS AND PSORIASE
MD480Z (en) * 2011-07-07 2012-09-30 Elvira Andon Method for treating acute ulcerative nonspecific colitis
US9892230B2 (en) 2012-03-08 2018-02-13 The Chinese University Of Hong Kong Size-based analysis of fetal or tumor DNA fraction in plasma
US10364467B2 (en) 2015-01-13 2019-07-30 The Chinese University Of Hong Kong Using size and number aberrations in plasma DNA for detecting cancer
CN107106541A (en) * 2015-01-28 2017-08-29 瑞采生技有限公司 Compounds for enhancing PPAR γ expression and nuclear translocation and medical uses thereof
US20180289708A1 (en) * 2015-10-15 2018-10-11 Moshe Rogosnitzky Low dose oral dipyridamole compositions and uses thereof
CN114432451B (en) * 2018-12-21 2024-02-09 广州市妇女儿童医疗中心 Immune mechanisms and therapeutic drugs for gastrointestinal diseases
CN111346228B (en) * 2018-12-21 2022-01-14 广州市妇女儿童医疗中心 Immunological mechanism of gastrointestinal tract disease and therapeutic medicine
ES3004516T3 (en) 2019-05-23 2025-03-12 Novartis Ag Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
CN113456618A (en) * 2020-03-31 2021-10-01 天津金耀集团有限公司 Compound dipyridamole inhalation preparation and preparation method thereof
EP4427752A1 (en) * 2023-03-09 2024-09-11 Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Dipyridamole as a novel therapy for muscular myogenesis disorders and inflammatory arthritis

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US579476A (en) * 1897-03-23 Sash-holder
US3031450A (en) * 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
AU496759B2 (en) * 1972-12-27 1978-10-26 Schering Aktiengesellschaft New pregnan-21-oic derivatives
US4107306A (en) 1973-01-16 1978-08-15 The Regents Of The University Of Michigan Process for treating proliferative skin disease
US4034087A (en) 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US3934036A (en) 1975-01-23 1976-01-20 Kyorin Seiyaku Kabushiki Kaisha N-benzenesulfonyl-β-alanine hydrazide useful as an immunosuppressive agent
FR2470599A1 (en) * 1979-12-07 1981-06-12 Panoz Donald IMPROVEMENTS IN PROCESSES FOR THE PREPARATION OF GALENIC SHAPES WITH DELAYED ACTION AND PROGRAMMED RELEASE AND GALENIC FORMS OF MEDICAMENTS THUS OBTAINED
DE3000979A1 (en) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach NEW DIPYRIDAMOL RETARD FORMS AND METHOD FOR THEIR PRODUCTION
BG36086A1 (en) * 1982-01-19 1984-09-14 Glbov Method for inducing interferon
US4387217A (en) * 1982-04-07 1983-06-07 Basf Wyandotte Corporation High foaming iodophors
JPS60174716A (en) 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd Medicinal patch
US4879119A (en) 1984-02-21 1989-11-07 Yamanouchi Pharmaceutical Co., Ltd. Patch
US4554271A (en) 1984-02-24 1985-11-19 The Upjohn Company Use of high doses of derivatives of 6α-methylprednisolone for the acute treatment of stroke syndrome
DE3627423A1 (en) 1986-08-13 1988-02-18 Thomae Gmbh Dr K MEDICINAL PRODUCTS CONTAINING DIPYRIDAMOL OR MOPIDAMOL AND O-ACETYLSALICYL ACID OR THEIR PHYSIOLOGICALLY COMPATIBLE SALTS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR COMBATING THROMBUS FORMATION
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
US5120716A (en) 1987-02-23 1992-06-09 Shiseido Company Ltd. Percutaneous absorption promoting agent and dermatologic preparation containing the same
US5668116A (en) 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
US5242921A (en) 1988-04-27 1993-09-07 Yale University Compositions and methods for treating cutaneous hyperproliferative disorders
AU3554089A (en) 1988-04-27 1989-11-24 Yale University Compositions and methods for treating cutaneous hyperproliferative disorders
WO1992016226A1 (en) 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
EG20321A (en) 1993-07-21 1998-10-31 Otsuka Pharma Co Ltd Medical material and process for producing the same
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
US5468729A (en) 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
DE4430128A1 (en) 1994-08-25 1996-02-29 Hoechst Ag Combination preparation with immunosuppressive, cardiovascular and cerebral effects
FR2732223B1 (en) 1995-03-30 1997-06-13 Sanofi Sa PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION
US5728712A (en) * 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6172066B1 (en) * 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6235706B1 (en) 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5874437A (en) 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
AU722480B2 (en) 1996-11-01 2000-08-03 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
CA2281224A1 (en) * 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
HUP0104439A3 (en) * 1997-03-18 2002-08-28 Basf Ag Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof
ES2131463B1 (en) * 1997-04-08 2000-03-01 Lilly Sa DERIVATIVES OF CYCLOPROPYLGLYCIN WITH PHARMACEUTICAL PROPERTIES.
ID23908A (en) 1997-06-05 2000-05-25 Lilly Co Eli TREATMENT METHOD OF TROMBOSIS DISEASE
US20030077229A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
EP1952802A3 (en) 1997-10-01 2009-06-17 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
AU4423799A (en) * 1998-06-04 1999-12-20 Cornell Research Foundation Inc. Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CN1246335A (en) * 1998-08-28 2000-03-08 冀聪韬 Process for preparing medicine used to treat dermatopathya
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6677326B2 (en) 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2001002497A1 (en) 1999-06-30 2001-01-11 Beltran, German Cuevas Process and product for rendering a substance flame resistant
US7358056B1 (en) * 1999-08-30 2008-04-15 Signal Pharmaceuticals Methods for modulating signal transduction mediated by TGF-β and related proteins
WO2001021163A2 (en) 1999-09-21 2001-03-29 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
WO2001024828A2 (en) * 1999-10-06 2001-04-12 Basf Aktiengesellschaft MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN αVβ3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
EP1093814A1 (en) 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
CA2392085A1 (en) * 1999-11-15 2001-05-25 Smithkline Beecham Corporation Carvedilol methanesulfonate
WO2001047572A2 (en) * 1999-12-29 2001-07-05 Advanced Cardiovascular Systems, Inc. Device and active component for inhibiting formation of thrombus-inflammatory cell matrix
US6363471B1 (en) * 2000-01-03 2002-03-26 Advanced Micro Devices, Inc. Mechanism for handling 16-bit addressing in a processor
US20020006435A1 (en) 2000-01-27 2002-01-17 Samuels Paul J. Transdermal anesthetic and vasodilator composition and methods for topical administration
DE10012555A1 (en) * 2000-03-15 2001-09-20 Merck Patent Gmbh Composition for rapid release of corticoid drugs after delay period, useful for drug delivery during the night, e.g. for preventing asthma, or for delivery to colon for treating inflammatory bowel disease
AU2001265111A1 (en) * 2000-05-30 2001-12-11 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
WO2002022127A1 (en) 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
IL140537A0 (en) * 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
JP2005506286A (en) 2001-03-02 2005-03-03 ブリストル−マイヤーズ　スクイブ　カンパニー Combined administration of melanocortin receptor agonist and phosphodiesterase inhibitor for the treatment of cyclic-AMP related diseases
US6759058B1 (en) 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
GB0119848D0 (en) * 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
EP2279742A3 (en) * 2001-10-05 2011-04-20 Zalicus Inc. Combinations for the treatment of immunoinflammatory disorders
AU2002346472A1 (en) 2001-11-20 2003-06-10 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
US6877326B2 (en) * 2002-03-20 2005-04-12 Lg Electronics Inc. Operation control apparatus and method of linear compressor
US20040180812A1 (en) 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
AU2003300469A1 (en) * 2002-12-31 2004-07-29 Larry L. Augsburger Methods for making pharmaceutical dosage forms containing active cushioning components
EP1594503A2 (en) 2003-02-07 2005-11-16 Boehringer Ingelheim International GmbH Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders
US20050058688A1 (en) 2003-02-22 2005-03-17 Lars Boerger Device for the treatment and prevention of disease, and methods related thereto
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US20070213308A1 (en) * 2006-01-26 2007-09-13 Lessem Jan N Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
BRPI0707325A2 (en) * 2006-01-27 2011-05-03 Eurand Inc multiparticulate release dosage formulation and method for preparing same
EP1993540A4 (en) * 2006-03-07 2010-06-09 Combinatorx Inc Compositions and methods for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
KR100824491B1 (en) 2008-04-22
HRP20040388A2 (en) 2004-10-31
RU2004113551A (en) 2005-02-27
SI1448205T1 (en) 2011-07-29
US20110223621A1 (en) 2011-09-15
TWI247605B (en) 2006-01-21
US20060234991A1 (en) 2006-10-19
CA2461946C (en) 2010-01-12
DK1448205T3 (en) 2011-12-12
CN1599613A (en) 2005-03-23
EP1448205B1 (en) 2011-03-23
AU2002334870B2 (en) 2007-10-04
PL370764A1 (en) 2005-05-30
AR036741A1 (en) 2004-09-29
US20030119786A1 (en) 2003-06-26
US7253155B2 (en) 2007-08-07
ATE502642T1 (en) 2011-04-15
WO2003030823A2 (en) 2003-04-17
KR20070100400A (en) 2007-10-10
IS7202A (en) 2004-03-31
PT1448205E (en) 2011-07-05
CN100400044C (en) 2008-07-09
BR0213100A (en) 2004-11-30
JP2005508346A (en) 2005-03-31
WO2003030823A3 (en) 2003-07-03
CA2461946A1 (en) 2003-04-17
US7915265B2 (en) 2011-03-29
KR100917082B1 (en) 2009-09-15
HK1076387A1 (en) 2006-01-20
EP2279742A3 (en) 2011-04-20
ES2363334T3 (en) 2011-08-01
MXPA04003266A (en) 2004-07-08
EP1448205A4 (en) 2007-01-03
NZ532310A (en) 2007-02-23
IL161267A0 (en) 2004-09-27
RU2322984C2 (en) 2008-04-27
KR20050033520A (en) 2005-04-12
AU2002334870B8 (en) 2003-04-22
EP2279742A2 (en) 2011-02-02
DE60239558D1 (en) 2011-05-05
ZA200402955B (en) 2005-04-19
EP1448205A2 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
NO20041386L (en) Combinations for the treatment of immuno-inflammatory disorders
NO20040097L (en) Combinations for the treatment of inflammatory disorders
NO20043237L (en) Dihydrobenzodiazepine-2-derivatives for the treatment of neurological disorders
NO20042680L (en) Processes for the preparation of O-demethylvenflaxine
NO20026263L (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
NO20035522D0 (en) Kinuclidine-substituted multicyclic heteroaryls for the treatment of disease
NO20024005L (en) Pteridine compounds for the treatment of psoriasis
NO20053384L (en) Benzazepine derivatives for the treatment of neurological disorders.
NO20020133D0 (en) Preparation for the treatment of external secretory disorders
NO20052894D0 (en) 4-tetrazolyl-4-phenylpiperidine derivatives for the treatment of pain
NO20043085L (en) Methods and compositions for the treatment of central nervous system disorders
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
NO20040253L (en) Methods for the treatment of liver fibrosis
NO20033803D0 (en) Carbamate for the treatment of movement disorders
DE60218451D1 (en) 15-KETO-PROSTAGLANDINE FOR THE TREATMENT OF DRUG-INDUCED OBSTIPATION
NO20033417L (en) Use of CD23 antagonists for the treatment of neoplastic disorders
NO20034123L (en) Procedure for the treatment of fuel
NO20033804L (en) Carbamate compounds for the treatment of pain
NO20035586L (en) Process for the preparation of cyclohexanol derivatives
NO20042476L (en) Use of desoxypeganine for the treatment of clinical depression
NO20012612D0 (en) Isonipecotamides for the treatment of integrin-mediated disorders
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
NO20043113L (en) Procedure for the treatment of bone disorder
NO20030717D0 (en) Compounds for the treatment of addiction disorders
EE200200670A (en) S-methyldihydroziprasidone for the treatment of psychiatric and ocular disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application